Cellectar Biosciences, Inc.
CLRB
$2.37
-$0.05-1.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.64M | 2.79M | 2.53M | 2.33M | 3.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.20M | 5.79M | 5.69M | 4.85M | 6.04M |
| Operating Income | -7.20M | -5.79M | -5.69M | -4.85M | -6.04M |
| Income Before Tax | -6.93M | -5.65M | -5.30M | -4.44M | -5.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.93M | -5.65M | -5.30M | -4.44M | -5.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.93M | -5.65M | -5.30M | -4.44M | -5.45M |
| EBIT | -7.20M | -5.79M | -5.69M | -4.85M | -6.04M |
| EBITDA | -7.16M | -5.74M | -5.64M | -4.80M | -5.98M |
| EPS Basic | -0.57 | -1.33 | -1.29 | -1.41 | -3.39 |
| Normalized Basic EPS | -0.35 | -0.83 | -0.81 | -0.88 | -2.12 |
| EPS Diluted | -0.57 | -1.33 | -1.29 | -1.41 | -3.39 |
| Normalized Diluted EPS | -0.35 | -0.83 | -0.81 | -0.88 | -2.12 |
| Average Basic Shares Outstanding | 12.23M | 4.24M | 4.11M | 3.16M | 1.61M |
| Average Diluted Shares Outstanding | 12.23M | 4.24M | 4.11M | 3.16M | 1.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |